Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,

#2133 Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms

Introduction: The high grade pancreatic neuroendocrine neoplasms (PanNENs) include well-differentiated tumors (WD-NETs) with elevated proliferation and poorly differentiated carcinomas (PD-NECs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Delektorskaya V, Solovieva O, Koslov N, Patyutko Y,

Keywords: neuroendocrine, pancreas, neoplasm, grade, survival,

#1911 Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

Introduction: The WHO 2010 classification has provided a valuable tool to stratify NEN prognosis based on an objective measure, the proliferation index. However, morphology and, in particular, tumor differentiation, is emerging again as a relevant feature that should not be dismissed due to its important clinical implications.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: García Carbonero R

Authors: Sánchez Cánovas M, Nuñez B, Benavent M, Teulé A, Segura A,

Keywords: WHO 2010 classification,

#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors

Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: olsen i

Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,

Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,

#920 High Grade (G3) Neuroendocrine Neoplasms Should Be Further Classified According to Morphological Differentiation

Introduction: Neuroendocrine neoplasms (NENs) with a Ki-67 >20% (Grade 3) are classified together as Neuroendocrine Carcinomas (NEC), and are usually considered as poorly differentiated. However Grade (G)3 NENs may be heterogeneous, with some demonstrating a well-differentiated cell morphology.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Mandair D, O'Leary J, Luong T, Thirlwell C, Meyer T,

Keywords: Ki-67, g3 NENs,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.